Exhibit 10.10


 



THIS WARRANT AND THE SECURITIES
ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THIS WARRANT AND PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.


 


	Date of Issuance	 	Void after
	January 28, 2021	 	December 14, 2030


 


CATABASIS PHARMACEUTICALS, INC.

ASSUMED WARRANT TO PURCHASE SHARES OF COMMON STOCK


 


This Assumed Warrant
(this “Warrant”) is issued to Viridian, LLC (the “Holder”) by Catabasis Pharmaceuticals, Inc., a Delaware
corporation (the “Company”). This Warrant and the Assumed Warrant to Purchase Shares of Preferred Stock of even date
herewith being issued by the Company to the Holder (the “Assumed Preferred Stock Warrant”) are being issued pursuant
to Section 7(b) of the Warrant to Purchase Shares of Common Stock issued by Quellis Biosciences, Inc. (“Quellis”)
to the Holder as of December 14, 2020 (the “Original Warrant”) to effectuate the assumption by the Company of
the Original Warrant pursuant to Section 3.2(b) of the Agreement and Plan of Merger, dated as of the date hereof (the
 “Merger Agreement”), among the Company, Quellis, Cabo Merger Sub I, Inc. and Cabo Merger Sub II, LLC. Capitalized
terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Merger Agreement.


 


	 	1.	Purchase of Shares.



 


(a)           Number
of Shares. Subject to the terms and conditions set forth herein (including the vesting conditions set forth in Subsection 2(b) below),
the Holder is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company
shall notify the Holder in writing), to purchase from the Company up to one hundred eighty-five thousand, one hundred thirty six
(185,136) fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common
Stock”).


 


(b)           Exercise
Price. The exercise price for the shares of Common Stock issuable pursuant to this Section 1 (the “Shares”)
shall be $0.35 per share (the “Exercise Price”). The Shares and the Exercise Price shall be subject to adjustment pursuant
to Section 7 hereof.


 






     


     


    

 


		2.	Exercise.



 


(a)           Exercise
Period. This Warrant shall be exercisable, in whole or in part, for the number of shares that have vested pursuant to Section 2(b) below
during the term commencing on the Date of Issuance and ending at 5:00 p.m. (Boston time) on December 14, 2030 (the “Exercise
Period”); provided, however, that this Warrant shall no longer be exercisable and become null and void ninety
(90) days after the cessation of the provision of services to the Company by Vahe Bedian.


 


(b)           Vesting.
On the last day of each one month period following December 21, 2018 (the “Vesting Commencement Date”), 2.08333%
of the Shares subject to this Warrant shall vest and be deemed exercisable hereunder. Subject to Section 19(b), if Vahe Bedian
ceases to provide services to the Company for any reason prior to the 4 year anniversary of the Vesting Commencement Date, any
further vesting shall automatically and immediately cease. The Company and the Holder may accelerate vesting of the Warrant upon
mutual written agreement.


 


		3.	Method of Exercise.



 


(a)           While
this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder may exercise, in whole or
in part, the vested purchase rights evidenced hereby. Such exercise shall be effected by:


 


(i)            the
surrender of the Warrant, together with a duly executed copy of the Notice of Exercise attached hereto, to the Secretary of the
Company at its principal office (or at such other place as the Company shall notify the Holder in writing); and


 


(ii)           the
payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased.


 


(b)            Each
exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this
Warrant is surrendered to the Company as provided in Section 3(a) above. At such time, the person or persons in whose
name or names any certificate for the Shares shall be issuable upon such exercise as provided in Section 3(c) below shall
be deemed to have become the holder or holders of record of the Shares represented by such certificate.


 


(c)           As
soon as practicable after the exercise of this Warrant in whole or in part, the Company at its expense will cause to be issued
in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes)
may direct:


 


(i)            a
certificate or certificates for the number of vested Shares to which such Holder shall be entitled, and


 


(ii)           in
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on
the face or faces thereof for the number of Shares equal to the number of such Shares described in this Warrant minus the number
of such vested Shares purchased by the Holder upon all exercises made in accordance with Section 3(a) above or Section 4
below.


 






    2 


     


    

 


4.            Net
Exercise. In lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value of this Warrant
(or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with notice
of such election (a “Net Exercise”). A Holder who Net Exercises shall have the rights described in Sections 3(b) and
3(c) hereof, and the Company shall issue to such Holder a number of Shares computed using the following formula:


 







 


Where


 


		X =	The number of Shares to be issued to the Holder.



 


		Y =	The number of vested Shares purchasable under this Warrant or, if only a portion of the Warrant
is being exercised, the vested portion of the Warrant being cancelled (at the date of such calculation).



 


		A =	The fair market value of one (1) Share (at the date of such calculation).



 


		B =	The Exercise Price (as adjusted to the date of such calculation).



 


For purposes of this
Section 4, the fair market value of a Share shall mean the average of the closing prices of a share of Common Stock quoted
in the over-the-counter market in which the Common Stock is traded or the closing price quoted on any exchange or electronic securities
market on which the Common Stock is listed, whichever is applicable, as published in The Wall Street Journal for the thirty
(30) trading days prior to the date of determination of fair market value (or such shorter period of time during which the Common
Stock was traded over-the-counter or on such exchange). If the Common Stock is not traded on the over-the-counter market, an exchange
or an electronic securities market, the fair market value shall be the price per Share that the Company could obtain from a willing
buyer for Shares sold by the Company from authorized but unissued Shares, as such prices shall be determined in good faith by the
Company’s Board of Directors.


 


5.             Representations
and Warranties of the Company. In connection with the transactions provided for herein, the Company hereby represents and warrants
to the Holder that:


 


(a)           Organization,
Good Standing, and Qualification.  The Company is a corporation duly organized, validly existing, and in good standing
under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted.
The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on its business or properties.


 






    3 


     


    

 


(b)           Authorization.
Except as may be limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the enforcement
of creditors’ rights, all corporate action has been taken on the part of the Company, its officers, directors, and stockholders
necessary for the authorization, execution and delivery of this Warrant. The Company has taken all corporate action required to
make all the obligations of the Company reflected in the provisions of this Warrant the valid and enforceable obligations they
purport to be. The issuance of this Warrant will not be subject to preemptive rights of any stockholders of the Company. The Company
has authorized sufficient shares of Common Stock to allow for the exercise of this Warrant.


 


6.             Representations
and Warranties of the Holder. In connection with the transactions provided for herein, the Holder hereby represents and warrants
to the Company that:


 


(a)           Authorization.
Holder represents that it has full power and authority to enter into this Warrant. This Warrant constitutes the Holder’s
valid and legally binding obligation, enforceable in accordance with its terms, except as may be limited by (i) applicable
bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors’ rights and
(ii) laws relating to the availability of specific performance, injunctive relief or other equitable remedies.


 


(b)           Purchase
Entirely for Own Account. The Holder acknowledges that this Warrant is entered into by the Holder in reliance upon such Holder’s
representation to the Company that the Warrant and the Shares (collectively, the “Securities”) will be acquired for
investment for the Holder’s own account, not as a nominee or agent, and not with a view to the resale or distribution of
any part thereof, and that the Holder has no present intention of selling, granting any participation in or otherwise distributing
the same. By acknowledging this Warrant, the Holder further represents that the Holder does not have any contract, undertaking,
agreement, or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with
respect to the Securities.


 


(c)           Disclosure
of Information. The Holder acknowledges that it has received all the information it considers necessary or appropriate for
deciding whether to acquire the Securities. The Holder further represents that it has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of the Securities.


 


(d)           Investment
Experience. The Holder is an investor in securities of companies in the development stage and acknowledges that it is able
to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business
matters that it is capable of evaluating the merits and risks of the investment in the Securities. If other than an individual,
the Holder also represents it has not been organized solely for the purpose of acquiring the Securities.


 


(e)           Accredited
Investor. The Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D, as presently
in effect, as promulgated by the Securities and Exchange Commission (the “SEC”) under the Act.


 






    4 


     


    

 


(f)            Restricted
Securities. The Holder understands that the Securities are characterized as “restricted securities” under the federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that
under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited
circumstances. In this connection, each Holder represents that it is familiar with Rule 144, as presently in effect, as promulgated
by the SEC under the Act (“Rule 144”), and understands the resale limitations imposed thereby and by the Act.


 


(g)           Bad
Actor Disqualification. The Holder is not subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to
(viii) under the Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3) under the Act.


 


(h)           Capitalization.
As of the Date of Issuance, Vahe Bedian, Jonathan Violin, Peter Harwin and Tomas Kiselak together constitute the beneficial owners
of not less than ninety percent (90%) of Holder’s membership interests. The Holder is not subject to any of the “Bad
Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Act.


 


(i)            Legends.
It is understood that the Securities may bear the following legend:


 


“THESE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED,
OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH A CERTAIN AGREEMENT BETWEEN THE COMPANY AND THE HOLDER AND PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.”


 


7.            Adjustment
of Exercise Price and Number of Shares. The number and kind of Shares purchasable upon exercise of this Warrant and the Exercise
Price shall be subject to adjustment from time to time as follows:


 


(a)           Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the issuance but prior to the expiration of this Warrant
subdivide its Common Stock, by split-up or otherwise, or combine its Common Stock, or issue additional shares of its Common Stock
as a dividend with respect to any shares of its Common Stock, the number of Shares issuable on the exercise of this Warrant shall
forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case
of a combination. Appropriate adjustments shall also be made to the Exercise Price payable per share, but the aggregate Exercise
Price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment
under this Section 7(a) shall become effective at the close of business on the date the subdivision or combination becomes
effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend.


 






    5 


     


    

 


(b)           Reclassification,
Reorganization and Consolidation. In case of any reclassification, capital reorganization or change in the capital stock of
the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 7(a) above),
then, as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right
at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this
Warrant, the kind and amount of shares of stock and other securities or property receivable in connection with such reclassification,
reorganization or change by a holder of the same number and type of securities as were purchasable as Shares by the Holder immediately
prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to
the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares
of stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise
Price per Share payable hereunder, provided the aggregate Exercise Price shall remain the same.


 


(c)           Notice
of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the
Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Shares or other
securities or property thereafter purchasable upon exercise of this Warrant.


 


8.             No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise
Price then in effect.


 


9.             No
Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder with
respect to the Shares, including (without limitation) the right to vote such Shares, receive dividends or other distributions thereon,
exercise preemptive rights or be notified of stockholder meetings, and, except as otherwise provided in this Warrant, such Holder
shall not be entitled to any stockholder notice or other communication concerning the business or affairs of the Company.


 






    6 


     


    

 


10.          Transfer
Restrictions. Notwithstanding anything contained herein to the contrary, this Warrant and all rights hereunder may not, in
whole or in part, be subject to any assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance, disposition
of or any other like transfer by the Holder to any person or entity without the prior written consent of the Company.


 


11.          Governing
Law. This Warrant shall be governed by and construed under the laws of the State of Delaware as applied to agreements among
Delaware residents, made and to be performed entirely within the State of Delaware.


 


12.          Successors
and Assigns. The terms and provisions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the
holders hereof and their respective successors and assigns.


 


13.          Titles
and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered in
construing or interpreting this Warrant.


 


14.          Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent
during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days
after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day
after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at the following addresses (or at such other addresses as shall be
specified by notice given in accordance with this Section 14):


 


If to the Company:


 


Catabasis Pharmaceuticals, Inc.


100 High St, 28th Floor


Boston, MA 02110


Attention: General Counsel


 


If to Holder:


 


At the address shown on the signature page hereto.


 






    7 


     


    

 


15.           Finder’s
Fee. Each party represents that it neither is or will be obligated for any finder’s fee or commission in connection with
this transaction. The Holder agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation
in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted liability) for
which the Holder or any of its officers, partners, employees or representatives is responsible. The Company agrees to indemnify
and hold harmless the Holder from any liability for any commission or compensation in the nature of a finder’s fee (and the
costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees
or representatives is responsible.


 


16.           Expenses.
If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the prevailing party shall be
entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party
may be entitled.


 


17.           Effectiveness;
Entire Agreement; Amendments and Waivers. This Warrant shall become effective, without further action by the Company or the
Holder, as of the First Effective Time. If (and for so long as) the First Effective Time does not occur, this Warrant shall be
of no force or effect. This Warrant, the Assumed Preferred Stock Warrant and any other documents delivered pursuant hereto constitute
the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and, without
limitation of the foregoing, the Holder agrees that, effective as of the First Effective Time, the Original Warrant shall be, and
hereby is, superseded in its entirety by this Warrant and the Assumed Preferred Stock Warrant and shall cease to be of any further
force or effect. Nonetheless, any term of this Warrant may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company
and the Holder; or if this Warrant has been assigned in part, by the holders or rights to purchase a majority of the shares originally
issuable pursuant to this Warrant.


 


18.           Severability.
If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall be excluded from this Warrant
and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms.


 


19.           Matters
Related to Merger.


 


(a)           Consent
to Treatment of Original Warrant. Notwithstanding anything else in the Original Warrant, the Holder consents and agrees to
the treatment of the Original Warrant as set forth in the Merger Agreement, including, without limitation, Section 3.2(b) thereof,
and acknowledges and agrees that the Original Warrant is superseded in its entirety by this Warrant and the Assumed Preferred Stock
Warrant.


 


(b)           Accelerated
Vesting. Any remaining unvested portion of this Warrant shall fully vest and become exercisable on the earlier to occur of
(i) the twelve (12)-month anniversary of the consummation of the First Effective Time, subject to Vahe Bedian’s continued
services to Catabasis or its affiliates through such date, and (ii) the date on which Vahe Bedian’s services with Catabasis
or its affiliates is terminated by Catabasis or its affiliates without “cause” (as such term is defined as of the date
hereof in the Catabasis Executive Severance Benefits Plan effective April 15, 2016).


 






    8 


     


    

 


(c)           Release
of Claims.


 


(i)            The
Holder acknowledges and agrees on behalf of itself and each of the Holder’s trustees, beneficiaries, directors, officers,
managers, employees, Affiliates, Subsidiaries, stockholders, members, partners, agents, representatives, heirs, executors, administrators,
estate, predecessors, successors and assigns (each, a “Holder Releasing Party”), that each Holder Releasing Party hereby
unconditionally, irrevocably and forever releases, acquits and discharges Quellis, the First Step Surviving Company, the Surviving
Company and the Company (each a “Company Beneficiary”) and each of such Company Beneficiary’s respective current
and former directors, officers, managers, employees, representatives, agents, members, stockholders, parents, Affiliates, Subsidiaries,
predecessors, successors, and assigns (each, a “Company Released Party” and collectively, the “Company Released
Parties”) from any and all rights, actions, causes of action, lawsuits, claims, controversies, demands, liabilities, obligations,
losses and damages (including reasonable attorneys’ fees and costs incurred or to be incurred) (collectively, “Claims”)
that arise out of or are related to the conduct, management or operation of the business and affairs of Quellis, or any act, omission,
event, or occurrence relating to (x) Quellis, (y) the Holder’s ownership of the Original Warrant, or (z) any
rights or interests in any other securities of Quellis (including any options to acquire capital stock of Quellis), in law or in
equity, known or unknown, suspected or unsuspected, matured or unmatured, contingent or vested, of any kind or nature or description
whatsoever, from the beginning of time to the First Effective Time, that any Holder Releasing Party had, presently has or may hereafter
have or claim or assert to have against any Company Released Party, including with respect to the treatment of the Original Warrant
in the Merger and/or any breach of fiduciary duty in connection with the approval of the Merger Agreement and the transactions
contemplated thereby that the Holder Releasing Party may have against the Company Released Parties; provided, however, that such
release shall not apply to (a) claims which may not be waived as a matter of law, or (b) any rights of any Holder Releasing
Party under (1) the Merger Agreement, (2) any agreement entered into by any Holder Releasing Party pursuant to the Merger
Agreement (including this Warrant) or (3) any indemnification or exculpation provisions set forth in the certificate of incorporation
or bylaws of Quellis or any indemnification agreement disclosed in the Company Disclosure Letter.


 


(ii)           The
Holder acknowledges that the Holder has read and understands Section 1542 of the Civil Code of the State of California (“Section 1542”),
which provides as follows:


 


A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE
CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF
KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.


 


Effective as of the First Effective Time,
the Holder waives and relinquishes on behalf of each Holder Releasing Party any rights and benefits which such Holder Releasing
Party may have under Section 1542 or any similar statute or common law principle of any jurisdiction. The Holder acknowledges
that the Holder may later discover facts different from, or in addition to, those the Holder now knows or believes to be true with
respect to the Claims released in this Section 19(c), and agrees the release in this Section 19(c) shall be and
remain in effect in all respects as a complete release as to all matters released, notwithstanding any such different or additional
facts. The Holder understands and acknowledges the significance and consequence of a waiver of Section 1542, and that such
waiver is an essential and material term of this Section 19(c).


 






    9 


     


    

 


(iii)          The
Holder acknowledges, covenants and agrees that (a) the Holder Releasing Parties have not made or filed any claim or proceeding
against any of the Company Released Parties in connection with, based upon or arising out of any released Claim, and (b) the
Holder Releasing Parties cannot and will not assign to any Person any released Claim (or any part thereof).


 


(iv)         The
Holder acknowledges that the Company would not enter into the Merger Agreement or consummate the Merger or other transactions contemplated
thereby but for the Holder’s willingness to agree to the release set forth in this Section 19(c).


 


[Signature Pages to Follow]


 






    10 


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Warrant as of the date first written above.


 


	 	CATABASIS PHARMACEUTICALS, INC.
	 	 
	 	By: 	/s/ Jill C. Milne                   
	 	Name: 	Jill C. Milne
	 	Title: 	President and Chief Executive Officer



 



	ACKNOWLEDGED AND AGREED:	 
	 	 
	HOLDER	 
	 	 
	Viridian, LLC	 
	 	 
	By: 	/s/ Jonathan Violin	
	Name:	Jonathan Violin	 
	Title: 	President	 



 


	Address:	203 Crescent Street, Building 17, Suite 102B	
	 	Waltham
MA 02453	



 


 






    11 


     


    

 


NOTICE
OF EXERCISE


 


Catabasis Pharmaceuticals, Inc.


 


Attention: Corporate Secretary


 


The undersigned hereby
elects to purchase, pursuant to the provisions of the Warrant, as follows:


 


		q	_____________ vested
Shares pursuant to the terms of the attached Warrant, and tenders herewith payment in cash of the Exercise Price of such Shares
in full, together with all applicable transfer taxes, if any.



 


		q	Net Exercise the attached
Warrant with respect to __________ vested Shares.



 


The undersigned hereby
represents and warrants that the Representations and Warranties in Section 6 hereof are true and correct as of the date hereof.


 


	 	HOLDER:




 


	Date:___________________	 	By:	 



 


		Address:	
	 	 	 
	 	 	 



 


Name in which shares should be registered: